姓名：陳策實(shí)

學(xué)歷：博士

專家類別：研究員,，博導(dǎo),、碩導(dǎo)

郵箱：[email protected]

通訊地址：云南省昆明市呈貢區(qū)雨花街道春融西路1168號(hào)

郵編：650500

簡(jiǎn)歷

1990.9-1994.7  理學(xué)學(xué)士,，南開大學(xué)生命科學(xué)院微生物系,。

1994.9-1999.6  理學(xué)博士，中國(guó)科學(xué)院上海生物工程研究中心和藥物研究所,。

1999.6-2002.4  博士后,，美國(guó)弗吉尼亞（Virginia）大學(xué)病理系。

2002.4-2004.6  博士后,，美國(guó)Emory 大學(xué)Winship 癌癥研究所,。

2004.7-2005.12 講師，美國(guó)Emory 大學(xué)Winship 癌癥研究所,。

2006.1-2009.10 助理教授（Tenure Track）,，美國(guó)阿爾巴尼醫(yī)學(xué)院細(xì)胞生物學(xué)癌癥研究中心。

2009.11-2010.10副教授（Tenure Track）,，美國(guó)阿爾巴尼醫(yī)學(xué)院細(xì)胞生物學(xué)和癌癥研究中心

2010.10-2022.8  研究員,，中國(guó)科學(xué)院昆明動(dòng)物研究所

2022.9-今  研究員，昆明醫(yī)科大學(xué)生物醫(yī)學(xué)工程研究院

2023年5月-至今 云南省腫瘤醫(yī)院副院長(zhǎng)

研究方向

主要圍繞乳腺癌發(fā)病機(jī)理進(jìn)行深入的系統(tǒng)研究,，對(duì)腫瘤遺傳、蛋白質(zhì)翻譯后修飾,、轉(zhuǎn)錄因子,、細(xì)胞周期與凋亡、細(xì)胞遷移和癌癥轉(zhuǎn)移,、信號(hào)傳導(dǎo),、代謝,、免疫、干細(xì)胞等方向感興趣,，在分子,、細(xì)胞、模式動(dòng)物和人等多個(gè)層次進(jìn)行重要基因的功能及其機(jī)制研究,，建立這些疾病的動(dòng)物模型用于腫瘤預(yù)防與藥物篩選,。同時(shí)與多家醫(yī)院展開合作，為預(yù)防和治療人類癌癥提供診斷/預(yù)后的分子標(biāo)志物以及治療靶標(biāo),。目前分為五個(gè)方向：

1.蛋白質(zhì)泛素化修飾與腫瘤

蛋白質(zhì)泛素化介導(dǎo)的降解可以調(diào)節(jié)細(xì)胞周期,，基因轉(zhuǎn)錄，DNA修復(fù),，遷移,，以及凋亡等細(xì)胞過程。蛋白質(zhì)泛素化需要三個(gè)酶相繼催化完成,，負(fù)責(zé)最后關(guān)鍵一步反應(yīng)的酶叫做E3泛素連接酶,，逆轉(zhuǎn)泛素化修飾的酶叫去泛素化酶（DUB）。我們發(fā)現(xiàn)很多E3和DUB,，如WWP1, Fbw7, HECTD3, RNF126, BCA2, BAP1,STAMBPL1等在乳腺癌中發(fā)生遺傳和表達(dá)畸變,。尋找、鑒定新的腫瘤相關(guān)的E3泛素連接酶和去泛素化酶,，研究它們作用的分子機(jī)制,，建立轉(zhuǎn)基因動(dòng)物模型，并開發(fā)它們?cè)谂R床診斷和治療的應(yīng)用是我們主要的一個(gè)研究方向,。

2.KLF5轉(zhuǎn)錄因子與乳腺癌干細(xì)胞

KLF5在基底型乳腺癌細(xì)胞中高表達(dá),。陽性KLF5的表達(dá)預(yù)示著病人生存時(shí)間短。我們多年的功能研究顯示KLF5能緊密控制FGF-BP,、mPGES1,、TNFAIP2和Slug癌基因表達(dá)，然后促進(jìn)細(xì)胞周期,、生存和腫瘤生長(zhǎng)和轉(zhuǎn)移,。KLF5的降解主要受到Fbw7和WWP1的控制。Hippo信號(hào)通路的YAP和TAZ共轉(zhuǎn)錄因子可以增加KLF5的穩(wěn)定性和活性,，從而促進(jìn)乳腺癌細(xì)胞增殖和生存,。KLF5的轉(zhuǎn)錄受到孕激素信號(hào)刺激后上調(diào)表達(dá)。我們發(fā)現(xiàn)乳腺特異性的KLF5 基因敲除小鼠乳腺發(fā)育延遲,。最近我們發(fā)現(xiàn)YB1是KLF5重要的上游正調(diào)控因子,，PRMT5可以催化KLF5蛋白發(fā)生甲基化而穩(wěn)定，HDAC1促進(jìn)KLF5去乙酰化而穩(wěn)定,。我們將進(jìn)一步研究KLF5在乳腺癌中的角色,、下游調(diào)節(jié)基因、相互作用蛋白以及上游調(diào)節(jié)因子,，以期能找到早期診斷預(yù)后標(biāo)志物以及控制這條途徑的藥物,。

3.表觀遺傳

非編碼RNA在人類基因組占比非常高，我們發(fā)現(xiàn)miRNA217和miR153在抑制KLF5表達(dá)方面發(fā)揮重要作用,，KLF5誘導(dǎo)的多條lncRNA如IGFL2-AS1, KPRT4, UCA1等介導(dǎo)了KLF5的促癌功能,。此外發(fā)現(xiàn)NSUN2介導(dǎo)的RNA的m5C修飾以及m5C的讀碼器YB1促進(jìn)基底型乳腺癌。IKKa催化的組蛋白H3磷酸化在炎癥介導(dǎo)的粘附分子表達(dá)和癌癥轉(zhuǎn)移中扮演關(guān)鍵角色,。計(jì)劃圍繞circRNA的編碼功能以及RNA的修飾展開研究,，以期能找到早期診斷預(yù)后標(biāo)志物和抗癌藥物靶標(biāo)。

4.腫瘤免疫

腫瘤免疫治療是近十多年來的一個(gè)熱門研究方向,，為癌癥的治療帶來了革命性變化,，我們發(fā)現(xiàn)KLF5通過促進(jìn)前列腺素產(chǎn)生導(dǎo)致免疫抑制微環(huán)境，HECTD3也通過調(diào)節(jié)免疫微環(huán)境中的巨噬細(xì)胞發(fā)揮重要作用,。擬從腫瘤疫苗,，CART新技術(shù)，多糖調(diào)節(jié)免疫系統(tǒng)抗癌等方面展開探索性研究,。

5.抗癌藥物研發(fā)

針對(duì)抗癌藥物靶點(diǎn)或細(xì)胞建立高通量篩選模型,，對(duì)天然產(chǎn)物和小分子化合物庫(kù)進(jìn)行篩選，發(fā)現(xiàn)中藥痛舒膠囊通過抑制ERa抑制乳腺細(xì)胞增殖,，升麻提取物KHF16通過抑制NFkB信號(hào)通路抑制三陰性乳腺癌,，避孕藥米非司酮以及衍生物、二甲雙胍,、光輝霉素,、超級(jí)增強(qiáng)子抑制劑JQ1/870和THZ1，PRMT5抑制劑PJ68等通過抑制KLF5抑制三陰性乳腺癌干細(xì)胞,。我們還對(duì)具有抗癌作用的先導(dǎo)化合物進(jìn)行結(jié)構(gòu)改造,，優(yōu)化生物活性，深入進(jìn)行藥理藥效學(xué)研究,，同時(shí)對(duì)外提供抗癌藥物評(píng)價(jià)和藥理研究服務(wù),。目前的課題聚焦在PROTAC化合物以及新型天然產(chǎn)物化合物的研發(fā)。

承擔(dān)科研項(xiàng)目

1)  國(guó)家自然科學(xué)基金重點(diǎn)項(xiàng)目：E3泛素連接酶RNF126通過調(diào)節(jié)DNA損傷修復(fù)促進(jìn)乳腺癌,，81830087,，2019年01月至2023年12月，直接費(fèi)用297萬元

2)  國(guó)家自然科學(xué)基金委-云南省聯(lián)合重點(diǎn)項(xiàng)目“KLF5通過相變和甲基化識(shí)別調(diào)控乳腺發(fā)育和基底型乳腺癌發(fā)生進(jìn)展的研究”U2102203,，2022年01月至2025年12月,，直接費(fèi)用233萬元

3)  國(guó)家重點(diǎn)研發(fā)計(jì)劃“干細(xì)胞及轉(zhuǎn)化研究”重點(diǎn)專項(xiàng): “上皮間質(zhì)相互轉(zhuǎn)換在乳腺（癌）干細(xì)胞中的功能,、分子機(jī)制和應(yīng)用研究”，首席科學(xué)家,，2020YFA0112300，2020.10-2025.1,，直接費(fèi)用2889萬元

4)  云南省科技廳基礎(chǔ)研究重點(diǎn)項(xiàng)目：KLF5/IGFL2-AS1/IGFL1軸線調(diào)控乳腺癌干細(xì)胞的功能和機(jī)制研究,，202101AS070050，2021-2024,，50萬元

5）云南省重大科技專項(xiàng)-生物醫(yī)藥專項(xiàng),，乳腺癌類器官庫(kù)及靶向示蹤診療技術(shù)平臺(tái)建設(shè)和運(yùn)用，首席科學(xué)家,，202302AA310046, 2023.6-2026.5,，2270萬元

6）云南省基礎(chǔ)研究重大項(xiàng)目， 首席孫漢董院士,，202201BC070002,，100萬元，參與

專家類別：

研究員,，百人計(jì)劃,，國(guó)家杰青，萬人計(jì)劃領(lǐng)軍人才,，云嶺學(xué)者

獲獎(jiǎng)及榮譽(yù)：

2021年 重慶市科技進(jìn)步獎(jiǎng)一等獎(jiǎng)（排名第2）

2018年 云嶺學(xué)者

2018年 中組部萬人計(jì)劃領(lǐng)軍人才

2016年 科技部中青年科技創(chuàng)新領(lǐng)軍人才

2015年云南省科技進(jìn)步獎(jiǎng)一等獎(jiǎng)（排名第5）

2013年 國(guó)家自然科學(xué)基金委杰出青年基金

2011年 中國(guó)科學(xué)院百人計(jì)劃A類擇優(yōu)（海外杰出科學(xué)家）

2010年 云南省高端科技人才

2008年 美國(guó)癌癥協(xié)會(huì)研究學(xué)者獎(jiǎng)

研究成果（論文,、專利、專著等）

近5年通訊作者研究論文：

2023年

1) A human-specific insertion promotes cell proliferation and migration by enhancing TBC1D8B expression,，Science China-Life Science,，2023，in press

2)  Zhenbin Wang, Lei Zhang, Bing Li, Jiagui Song, Miao Yu, Jing Zhang, Ceshi Chen*, Jun Zhan*, Hongquan Zhang*, Kindlin-2 in myoepithelium controls luminal progenitor commitment to alveoli in mouse mammary gland, Cell Death & Disease volume 14, article number: 675 (2023) 

3) Ting Qiu#, Lei Hou#, Lina Zhao#, Xinye Wang, Zhongmei Zhou, Chuanyu Yang, Huifeng Zhang, Dewei Jiang*, Baowei Jiao*, Ceshi Chen*,，SGCE promotes breast cancer stemness by promoting the transcription of FGF- BP1 by Sp1, J Bio Chem,，2023, 299(11):105351

4) Huan Fang#，Wenlong Ren#,，Qiuxia Cui#,，Huichun Liang，Chuanyu Yang,， Wenjing Liu,，Xinye Wang，Xue Liu,，Yujie Shi*,，Jing Feng*，Ceshi Chen*,，Integrin β4 promotes DNA damage drug resistance in triple-negative breast cancer via the TNFAIP2/IQGAP1/Rac1 axis,，Elife, 2023 Oct 3:12:RP88483. doi: 10.7554/eLife.88483.

5）Jia He#, Luzhen Wang#, DaZhao Mi#, Tian Guan#, Wenjing Liu, Peng He, Haijun Gu, Yuzhan Li, Yangrui Peng, Ai-Qun Jia, Ceshi Chen*, Yihua Chen*,，Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer，J Med Chem,，2023 Jun 8;66(11):7421-7437

6) Qiuxia Cui#, Jian Sun#, Huiping Yuan#, Juanjuan Li, Chuanyu Yang, Guangshi Du, Chengang Zhou, Pu Qiu, Jidong Gao, Yuanqi Zhang*, Dewei Jiang*, Ceshi Chen*, DNA damage chemotherapeutic drugs suppress basal like breast cancer growth through downregulating the transcription of FOXO1-KLF5 axis, Gene&Diseases, 2023, May 2;11(1):91-94.

7) Ping Zhao#, Jian Sun#, Xinwei Huang#, Xiangwu Zhang, Xin Liu, Rong Liu, Guangshi Du, Wenqiang Gan, Chuanyu Yang, Yiyin Tang*, Ceshi Chen*, Dewei Jiang*, Targeting the KLF5-EphA2 axis can restrain cancer stemness and overcome chemoresistance in basal-like breast cancer, Int. J. Biol. Sci. 2023; Mar 21;19(6):1861-1874.

8) Qi Wu#, Zhou Liu#, Zhijie Gao#, Yao Luo#, Fubing Li, ChuanYu Yang, Tiantian Wang, Xiangyu Meng, Haijun Chen, Juanjuan Li, Yanjie Kong*, Chao Dong*, Si Sun*, Ceshi Chen*,，KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8+ T-cell-dependent antitumor immunity，Theranostics,，2023; 13(4): 1381-1400.

9) Luzhen Wang#, Dazhao Mi# , Jinhui Hu#, Wenjing Liu, Yi Zhang, Chunyan Wang *, Yihua Chen*, Ceshi Chen *,，A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer，Cancer Letters,，555 (2023) 216049.

10) Li Zeng#, Hongyan Zhang#, Chuanyu Yang, Zhuo Cheng ,Qiuyun Jiang, Yao Luo, Yi Li, Fubing Li*, Ceshi Chen* , Generation of a tree shrew breast cancer model using lentivirus expressing PIK3CA-H1047R, Zoological Res, 2023, 44(1): 94?97

11) Wenjing Liu, Min Zheng, Rou Zhang, Qiuyun Jiang, Guangshi Du, Yingying Wu, Chuanyu Yang, Fubing Li, Wei Li, Luzhen Wang, Jiao Wu, Lei Shi, Wenhui Li, Kai Zhang, Zhongmei Zhou, Rong Liu, Yingzheng Gao, Xinwei Huang, Songqing Fan, Xu Zhi*, Dewei Jiang*, Ceshi Chen*, RNF126-Mediated MRE11 Ubiquitination Activates the DNA Damage Response and Confers Resistance of Triple-Negative Breast Cancer to Radiotherapy, Adv Sci, 2023 Vol. 10 Issue 5 Pages e2203884. 

2022年

1)  Fubing Li#, Huichun Liang#, Hua You, Ji Xiao, Houjun Xia, Xi Chen, Maobo Huang, Zhuo Cheng, Chuanyu Yang, Wenjing Liu, Hailin Zhang, Li Zeng, Yingying Wu, Fei Ge, Zhen Li, Wenhui Zhou, Yi Wen, Zhongmei Zhou, Rong Liu, Dewei Jiang, Ni Xie, Bin Liang, Zhenzhen Liu*, Yanjie Kong*, Ceshi Chen*,，HECTD3 promotes tumor metastasis by ubiquitinating IKKa to upregulate expression of adhesion molecules in vascular endothelial cells,Signal Transduction and Targeted Therapy，(2022) 7:264

2)  Guangshi Du#, Jian Sun#, Zhen Li#, Qian Zhang, Wenjing Liu, Chuanyu Yang, Ping Zhao, Xinye Wang, Qiyan Yin, Yao Luo, Jinhuan Song, Yi Wen, Haixia Wang, Chuan-Huizi Chen, Guosheng Hu, Zhongmei Zhou, Xiaoyun Mao, Wen Liu, Zhenzhen Liu*, Dewei Jiang*, Ceshi Chen*,A feedforward circuit between KLF5 and lncRNA KPRT4 contributes to basal-like breast cancer,Cancer Letters,Volume 534,2022,215618

3)  Yanjie Kong#, Wenlong Ren#, Huan Fang#, Naseer Ali Shah#, Yujie Shi, Dingyun You, Chengang Zhou, Dewei Jiang, Chuanyu Yang, Huichun Liang, Wenjin Liu, Luzhen Wang, Wenqiang Gan, Xing Wan, Fubing Li*, Zhen Li*, Ceshi Chen*, and Ni Xie* , Histone Deacetylase Inhibitors (HDACi) Promote KLF5 Ubiquitination and Degradation in Basal-like Breast Cancer,Int J Biol. Sci., 2022; 18(5): 2104–2115.

4)  Rong Liu#*, Guangxi Yang#, Min Bao#, Zhongmei Zhou, Xiaoyun Mao,Wenjing Liu, Xiaoyan Jiang, Di Zhu, Xinle Ren, Jian Huang*, Ceshi Chen*, STAMBPL1 promotes breast cancer cell resistance to cisplatinpartially by stabilizing MKP-1 expression,Oncogene, 2022,；41, 2265–2274

5)  Dewei Jiang#, Ting Qiu#, Junjiang Peng#, Siyuan Li#, Tala, Wenlong Ren, Chuanyu Yang, Yi Wen,Chuan-HuiziChen, Jian Sun, Yingying Wu, Rong Liu, Jun Zhou, Kongming Wu, Wen Liu, Xiaoyun Mao*, Zhongmei Zhou*, Ceshi Chen*,，YB-1 is a positive regulator of KLF5 transcription factor in basal-like breast cancer，Cell Death and Differentiation, 2022

2021年

1)  Jian Sun#, Wenjing Liu #, Yongbo Guo, Hailin Zhang, Dewei Jiang, Ying Luo, Rong Liu, Ceshi Chen*, Characterization of tree shrew telomeres and telomerase,Journal of Genetics and Genomics, 2021,，48,，631-639

2)  Haixia Wang#, Yujie Shi#, Chuan-Huizi Chen, Yi Wen, Zhongmei Zhou, Chuanyu Yang,Jian Sun, Guangshi Du, Jiao Wu, Xiaoyun Mao, Rong Liu, Ceshi Chen, KLF5-induced lncRNA IGFL2-AS1 promotes basal-like breast cancer cellgrowth and survival by upregulating the expression of IGFL1,Cancer Letters, 2021,515: 49-62

3)  Xinye Wang#, Ting Qiu#, Yingying Wu, Chuanyu Yang, Yi Li, Guang-Shi Du, Yaohui He, Wen Liu, Rong Liu, Chuan-Huizi Chen, Yu-Jie Shi, Jingxuan Pan, Jia Zhou, Dewei Jiang*, and Ceshi Chen*, Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal like breast cancer,Cell Death and Differentiation, 2021;28(10):2931-2945.

4)  Jiao Wu#, Sai-Ching Jim Yeung#, Sicheng Liu#, AihamQdaisat, Dewei Jiang, Wenli Liu, Zhuo Cheng, Wenjing Liu, Haixia Wang, Lu Li, Zhongmei Zhou, Rong Liu, Chuanyu Yang, Ceshi Chen*, Runxiang Yang*, Cyst(e)ine in Nutrition Formulation Promotes Colon Cancer Growth and Chemoresistance by Activating mTORC1 and Scavenging ROS,Signal Transduction and Targeted Therapy，2021,，6:188

5)  Maobo Huang#, Yuanfei Zhou#, DongzhuDuan#, Chuanyu Yang, Zhongmei Zhou, Fubing Li, Yanjie Kong, Yi-Ching Hsieh, Ruihan Zhang, Wenping Ding, Weilie Xiao, PemaTenzin Puno*, Ceshi Chen*, Targeting ubiquitin conjugating enzyme UbcH5b by a triterpenoid PC3-15 from Schisandra plants sensitizes triple-negative breast cancer cells to lapatinib,Cancer Letters, 2021, 504,，125-36

6)  Benfu Zhong#, Dewei Jiang#, Yang Hong, Lifang Li, Li Qiu, Ronghui Yang, XiaohanJin, Yawen Song, Ceshi Chen*, Binghui Li*, Glucose-6-phosphate dehydrogenase neutralizes stresses by supporting reductive glutamine metabolism and AMPK activation，Signal Transduction and Targeted Therapy,，2021,6(46)

7)  Xiaoyan Jiang#, Xu Zhi#, Peixia Zhang, Zhongmei Zhou, Jinxiang Ye, Yu Gao, Xinye Wang, Chuanyu Yang, Haijun Chen*, Rong Liu* and Ceshi Chen*, Isochromanoindolenines suppress triple-negative breast cancer cell proliferation partially via inhibiting Akt activation,Int J Biol. Sci., 2021; 17(4):986-994

2020年

1)    Danping Wang#, ZhiNie#, Xiaoyan Jiang, Jinxiang Ye, Zhimin Wei, Dating Cheng, Chenyang Wang, Yingying Wu, Rong Liu*, Haijun Chen*, Ceshi Chen*, Chunyan Wang*, Pyrrolo[3,4-b]-quinolin-9-amine compound FZU-0038-056 suppresses triple-negative breast cancer partially through inhibiting the expression of Bcl-2 ,Aging, 2020, May 23;12.

2)  Lina Zhao#, Ting Qiu#, Dewei Jiang#, Haibo Xu, Li Zou, Qin Yang, Ceshi Chen *, Baowei Jiao*, SGCE promotes breast cancer stem cells by stabilizing EGFR,Advanced Science, 2020, https://doi.org/10.1002/advs.201903700

3)  Wenjing Liu#, Xiaoqing Lu#, Peiguo Shi#, Guangxi Yang, Zhongmei Zhou, Wei Li, Xiaoyun Mao*, Dewei Jiang* & Ceshi Chen*, TNF-a increases breast cancer stem-like cells through upregulating TAZ expression via the non-canonical NF-kB pathway,Scientific Reports, 10, 1804 (2020). https://doi.org/10.1038/s41598-020-58642-y

4)   Rong Liu#, Haijun Chen#, Ping Zhao, Chuan-Huizi Chen, Huichun Liang, Chuanyu Yang, Zhongmei Zhou, Xu Zhi, Suling Liu, Ceshi Chen*,，Mifepristone Derivative FZU-00,003 Suppresses Triple-negative Breast Cancer Cell Growth partially via miR-153-KLF5 axis,Int J Biol. Sci., 2020; 16(4):611-619

5)  Rui-DanBao, Xue-QingSong, Yan-jieKong, Fang-FangLi, Wen-HuiLiao, JieZhou, Ji-hongZhang, Qi-HuaZhao, Jing-YuanXu, Ce-shiChen*, Ming-JinXie*, A new Schiff base copper(II) complex induces cancer cell growth inhibition and apoptosis by multiple mechanisms, Journal of Inorganic Biochemistry, 2020, Jul;208:111103.

2019年

1)   Yingying Wu, QunyingQin ,Fubing Li , Chuanyu Yang , Zhen Li , Zhongmei Zhou , Hailin Zhang , Yunxi Li , Xinye Wang , Rong Liu , Qian Tao , Wenlin Chen*, Ceshi Chen*, USP3 promotes breast cancer cell proliferation by deubiquitinating KLF5,J. Biol. Chem.2019, 294(47)，17837-47

2)  LingliHe , Liang Yuan , Yang Sun , Pingyang Wang , Hailin Zhang , Xue Feng , Zuoyun Wang , Wenxiang Zhang , Chuanyu Yang , Yi Arial Zeng , Yun Zhao , Ceshi Chen*, Lei Zhang*, Glucocorticoid receptor signaling promotes breast cancer progression by activating TEAD4,CancerRes, 2019, 79(17):4399-4411.

3)  Yanjie Kong*, Zehua Wang*, Maobo Huang, Zhongmei Zhou, Yi Li, Huilai Miao, Xing Wan, Jian Huang, Xiaoyun Mao#, Ceshi Chen#, CUL7 promotes cancer cell survival through promoting Caspase-8 ubiquitination,Int J Cancer,2019 ,，145(5)：1371-1381

4)  Wenhui Zhou#, Huan Fang#, Qiuju Wu#, Xinye Wang, Rong Liu, Fubin Li, Ji Xiao, Lin Yuan, Zhongmei Zhou, Junying Ma, Lulu Wang, Weiwei Zhao, Hua You, Jianhua Ju, Jing Feng*, Ceshi Chen*, Ilamycin E, a natural product of marine actinomycete, inhibits triple-negative breast cancer partially through ER stress-CHOP-Bcl-2,Int J Biol. Sci., 2019; 15(8): 1723-1732

5)  Chuan-Huizi Chen, Nong Yang, Yongchang Zhang, Jiancheng Ding, Wenjuan Zhang, Rong Liu, Wen Liu*, Ceshi Chen*, Inhibition of super enhancer downregulates the expression of KLF5 in basal-like breast cancers,Int J Biol. Sci., 2019; 15(8): 1733-1742.

近5年綜述論文：

1)  Qiyan Yin#, Min Zheng#, Qianmei Luo, Dewei Jiang, Huifeng Zhang*, Ceshi Chen*, YB-1 as an oncoprotein: functions, regulation, post-translational modifications, and targeted therapy,Cells, 2022

2)  Xuerong Wang#, Chao Wang#, Jiaheng Guan#, Baoan Chen,Lin Xu*, Ceshi Chen*,，Progresses of breast cancer basic research in China，Int J Biol. Sci.,2021; 17(8): 2069-2079.

3)  Yao Luo, Ceshi Chen, The Roles and Regulation of the KLF5 Transcription Factor in Cancers,Cancer Science, 2021,，112(6): 2097–2117.

4)  Ping Zhao#, Dewei Jiang#, Yunchao Huang*, Ceshi Chen*, EphA2: a promising therapeutic target in breast cancer,Journal of Genetics and Genomics, 2021,，48(4):261-267.

5)  Chao Dong#, Jiao Wu#, Yin Chen, JianyunNie* and Ceshi Chen*, Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer,Front. Pharmacol.  2021, 12:628690. doi: 10.3389/fphar.2021.628690

6)  Zhen Li, Wei Zou, Ji Zhang, Yunjiao Zhang, Qi Xu, Siyuan Li, Ceshi Chen*, Mechanisms of CDK4/6 inhibitor resistance in luminal breast cancer，F(xiàn)ront. Pharmacol. 11:580251. doi: 10.3389/fphar.2020.580251

7)  Li Zeng, Wei Li, Ceshi Chen*, Breast cancer animal models and applications,Zoological Research, 2020, Sep 18;41(5):477-494. doi: 10.24272/j.issn.2095-8137.2020.095.

8)  RouZhang, WenjinLiu, JianSun, YanjieKong, Ceshi Chen*, Roles of RNF126 and BCA2 E3 ubiquitin ligases in DNA damage repair signaling and targeted cancer therapy, Pharmacological Research, 6 March 2020, https://doi.org/10.1016/j.phrs.2020.104748

9)  Qiuyun Jiang, Fubing Li, Zhuo Cheng, Yanjie Kong, Ceshi Chen*, The role of E3 ubiquitin ligase HECTD3 in cancer and beyond,Cellular and Molecular Life Sciences, 2019, Oct 21. doi: 10.1007/s00018-019-03339-3.

10)  Lin Jia, Yundong Shi, Yi Wen, Wei Li, Jing Feng, Ceshi Chen*, The roles of TNFAIP2 in cancers and infectious diseases,J Cell Mol Med.2018;22:5188–5195.

近5年非SCI論文以及專著

1)  鄭敏,，李薇,，陳策實(shí)，精準(zhǔn)腫瘤學(xué),，第43章細(xì)胞培養(yǎng)和動(dòng)物模型的建立,，科學(xué)出版社，p 329-355,，2022年10月第一版,。

2)  陳策實(shí)，青年醫(yī)師如何做好科研,，中華乳腺病雜志（電子版）,，2022,，16（1）：28

3)  Yingying Wu, Qiuting Zhang, and Ceshi Chen，Heterogeneity and Subtyping of Triple-Negative Breast Cancer (Book Chapter), Triple-Negative Breast Cancer, World Scientific, 2021, ISBN, 978-3277-75-5, 21-40.

4)  李富兵,，陳策實(shí),，泛素家族介導(dǎo)的蛋白質(zhì)降解和細(xì)胞自噬，第十六章泛素化調(diào)節(jié)細(xì)胞死亡,，科學(xué)出版社,，p389-417，2020年6月第一版,。

5）侯雷，羅倩梅,，李玲睿,，陳策實(shí)，類器官及其應(yīng)用,，上?？茖W(xué)技術(shù)出版社，第九章,，乳腺癌類器官,，p225-246，2023年11月第一版

專利：

1）一種乳頭注射慢病毒建立樹鼩乳腺癌模型的方法 專利號(hào)：ZL201310133542.1授權(quán)日期20150218, 陳策實(shí),、夏厚軍,、何保麗、角建林

2）米非司酮衍生物及其用途 專利號(hào)：CN106397527 B授權(quán)日期：2019年7月26日, 陳策實(shí),、陳海軍,、劉蓉

3）3 ,4斷裂的環(huán)阿爾廷型三萜類化合物在制備自噬抑制劑及抗腫瘤藥物中的應(yīng)用，申請(qǐng)?zhí)?02010405627 .0,，申請(qǐng)日2020 .05 .14,，陳策實(shí) 普諾·白瑪?shù)ぴ?emsp;孫漢董 黃茂波 周元飛

4）一類誘導(dǎo)腫瘤細(xì)胞發(fā)生Methuosis死亡的三芳香雜環(huán)哌嗪類化合物及其應(yīng)用，陳益華,，陳策實(shí),，何佳等，2023年,，申請(qǐng)中